Lessons from TGF-β transgenic mice

Mineral and Electrolyte Metabolism

Volumn 24, Issue 2-3, 1998, Pages 154-160

  Böttinger, Erwin P ^a   Kopp, Jeffrey B ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Development; Disease; Fibrosis; Inflammation; TGF ; Transgenic mice

Indexed keywords

ALBUMIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; FIBROSIS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; DISEASE; GENE EXPRESSION; HUMANS; MICE; MICE, TRANSGENIC; MUTAGENESIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS MUSCULUS;

EID: 0031932998     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057364     Document Type: Review

References (52)

1. Racke MK, Cannella B, Albert P, Sporn M, Raine CS, McFarlin DE: Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol 1992;4:615-620.
2. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ: Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991;88:2918-2921.
3. Barrai A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed S, Carvalho EM, Barral-Netto M: Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol 1995;147:947-954.
4. Flanders KC, Lippa CF: TGF-β2 in neurodegenerative disease. Neural Notes 1996;2:8-10.
5. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
6. Markowitz SD, Roberts AB: Tumor suppressor activity in the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996;1:93-102.
7. Roberts AB: Transforming growth factor-β: Activity and efficacy in animal models of wound healing. Wound Rep Reg 1995;3:408-418.
8. Gold LI, Korc M: Expression of transforming growth factor-β1, 2, and 3 mRNA and protein in human cancers. Dig Surg 1994;11:150-156.
9. Böttinger EP, Jakubczak JL, Roberts ISD, Mumy M, Hemmati P, Bagnall K, Merlino G, Wakefield LM: Expression of a dominant negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J 1997;16:2621-2633.
10. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β1 knockout mice. J Immunol 1995;155:3205-3212.
11. Fowlis DJ, Cui W, Johnson SA, Balmain A, Akhurst RJ: Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor-β1 in the skin of transgenic mice. Cell Growth Differ 1996;7:679-687.
12. Cui W, Fowlis DJ, Cousins FM, Duffie E, Bryson S, Balmain A, Akhurst RJ: Concerted action of TGF-beta 1 and its type II receptor in control and epidermal homeostasis in transgenic mice. Genes Dev 1995;9:945-955.
13. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92:2572-2576.
14. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS: Transgenic mice with increased levels of TGF-β1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
15. Böttinger EP, Letterio JL, Roberts AB: Biology of TGF-β in knockout and transgenic mouse models. Kidney Int 1997;51:1355-1360.
16. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497.
17. Johnson RJ: The glomerular response to injury: Progression or resolution. Kidney Int 1994;45: 1769-1782.
18. Savage COS: The biology of the glomerulus: Endothelial cells. Kidney Int 1994;45:314-319.
19. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5: 1273-1287.
20. Erlebacher A, Derynck R: Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996;132:195-210.
21. Böttinger EP, Factor VM, Tsang ML-S, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB: The recombinant proregion of transforming growth factors-β1 (latency-associated peptide) inhibits active transforming growth factor β1 in transgenic mice. Proc Natl Acad Sci USA 1996;93: 5877-5882.
22. Russell WE, Coffey RJ Jr, Ouellette AJ, Moses HL: Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 1988;85:5126-5130.
23. Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Campbell A, Lucia MS, Sporn MB, Roberts AB: Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric synthase in vivo in the transforming growth factor beta 1 null mouse. J Exp Med 1996;183:2337-2342.
24. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RSH, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA, Sporn MB: Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995;1:129-136.
25. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL: Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-1598.
26. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y: Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994; 73:2275-2279.
27. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J: Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 1995;1:282-284.
28. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995;1:74-79.
29. Dickson K, Philip A, Warshawsky H, O'Connor-McCourt M, Bergeron JJ: Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest 1995;95: 2539-2554.
30. Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird A: Enhanced expression and transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Res 1992;586:216-225.
31. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, Mucke L: Increased central nervous production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol 1995;147:53-67.
32. Galbreath E, Kim SJ, Park K, Brenner A: Overexpression of TGF-beta 1 in the central nervous system of transgenic mice results in hydrocephalus. J Neuropathol Exp Neurol 1995; 54:339-349.
33. Sellheyer K, Bickenbach JR, Rothnagel JA, Bundman D, Longley MA, Krieg T, Roche NS, Roberts AB, Roop DR: Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice. Proc Natl Acad Sci USA 1993;90: 5237-5241.
34. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ: TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-542.
35. Daniel CW, Silberstein GB, Van Horn K, Strickland P, Robinson S: TGF-beta 1-induced inhibition of mouse mammary ductal growth: Developmental specificity and characterization. Dev Biol 1989;135:20-30.
36. Robinson SD, Silberstein GB, Roberts AB, Flanders KC, Daniel CW: Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development 1991; 113:867-878.
37. Silberstein GB, Flanders KC, Roberts AB, Daniel CW: Regulation of mammary morphogenesis: Evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol 1992; 152:354-362.
38. Wakefield LM, Sporn MB: Suppression of carcinogenesis: A role for TGF-β and related molecules in prevention of cancer, in Klein G (ed): Tumor Suppressor Genes, chap 11, 1991.
39. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen L, Roberts AB, Smith GH, Merlino G: Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 1993;12:1835-1845.
40. Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL, Moses HL: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 1993;7:2308-2317.
41. Pierce DFJr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr, Moses HL: Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 1995;92:4254-4258.
42. Zhou L, Chitta RD, Wert SE, Whitsett JA: Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-β1 chimeric gene. Dev Biol 1996;175:227-238.
43. Serra R, Pelton RW, Moses HL: TGF beta 1 inhibits branching morphogenesis and N-myc expression in lung bud organ cultures. Development 1994;120:2153-2161.
44. Lee MS, Gu D, Feng L, Curriden S, Arnush M, Krahl T, Gurushanthaiah D, Wilson C, Loskutoff DL, Fox H, Sarvetnick N: Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am J Pathol 1995;147:42-52.
45. Sanvito F, Nichols A, Herrera PL, Huarte J, Wohlwend A, Vassali JD, Orci L: TGF-beta 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-alpha, triggers insulin-dependent diabetes. Biochem Biophys Res Commun 1995;217:1279-1286.
46. Lee MS, Sawyer S, Arnush M, Krahl T, von Herrath M, Oldstone MBA, Sarvetnick N: Transforming growth factor-β fails to inhibit allograft rejection or virus-induced autoimmune diabetes in transgenic mice. Transplantation 1996;61:1112-1113.
47. Noda M, Camilliere JJ: In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 1989;124:2991-2994.
48. Joyce ME, Roberts AB, Sporn MB, Bolander ME: Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990;110:2195-2207.
49. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF: Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 1989;264:13660-13664.
50. Miyazono K, Heldin CH: Latent forms of TGF-beta: Molecular structure and mechanisms of activation (discussion). Ciba Found Symp 1991;157:81-89.
51. Flaumenhaft R, Kojima S, Abe M, Rifkin DB: Activation of latent transforming growth factor beta. Adv Pharmacol 1993;24:51-76.
52. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE: Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1994;269: 26775-26782.